Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial - Dimopoulos, Meletios A.; Oriol, Albert; Nahi, Hareth; San-Miguel, Jesus; Bahlis, Nizar J.; Usmani, Saad Z.; Rabin, Neil; Orlowski, Robert Z.; Suzuki, Kenshi; Plesner, Torben; Yoon, Sung-Soo; Ben Yehuda, Dina; et al. (Journal of clinical oncology, 2023)
Gesehen am 04.09.2023